...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Engineering pro-angiogenic peptides using stable, disulfide-rich cyclic scaffolds.
【24h】

Engineering pro-angiogenic peptides using stable, disulfide-rich cyclic scaffolds.

机译:使用稳定的富含二硫键的环状支架工程化促血管生成肽。

获取原文
获取原文并翻译 | 示例

摘要

Fragments from the extracellular matrix proteins laminin and osteopontin and a sequence from VEGF have potent proangiogenic activity despite their small size (< 10 residues). However, these linear peptides have limited potential as drug candidates for therapeutic angiogenesis because of their poor stability. In the present study, we show that the therapeutic potential of these peptides can be significantly improved by "grafting" them into cyclic peptide scaffolds. Momordica cochinchinensis trypsin inhibitor-II (MCoTI-II) and sunflower trypsin inhibitor-1 (SFTI-1), naturally occurring, plant-derived cyclic peptides of 34 and 14 residues, respectively, were used as scaffolds in this study. Using this approach, we have designed a peptide that, in contrast to the small peptide fragments, is stable in human serum and at nanomolar concentration induces angiogenesis in vivo. This is the first report of using these scaffolds to improve the activity and stability of angiogenic peptide sequences and is a promising approach for promoting angiogenesis for therapeutic uses.
机译:来自细胞外基质蛋白层粘连蛋白和骨桥蛋白的片段以及来自VEGF的序列尽管大小小(<10个残基),却具有强大的促血管生成活性。但是,这些线性肽由于其不良的稳定性而作为治疗血管生成的候选药物的潜力有限。在本研究中,我们表明通过将它们“移植”到环状肽支架中可以显着提高这些肽的治疗潜力。苦瓜中的胰蛋白酶抑制剂II(MCoTI-II)和向日葵胰蛋白酶抑制剂1(SFTI-1)分别是天然存在的植物衍生的环肽,分别具有34和14个残基,被用作支架。使用这种方法,我们设计了一种肽,该肽与小肽片段相反,在人血清中稳定,并且在纳摩尔浓度下诱导体内血管生成。这是使用这些支架来改善血管生成肽序列的活性和稳定性的第一份报道,并且是促进用于治疗用途的血管生成的有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号